Brain-Computer Interface Implant for Severe Communication Disability
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04576650|
Recruitment Status : Withdrawn (Investigational device no longer available. No subjects enrolled.)
First Posted : October 6, 2020
Last Update Posted : November 7, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Locked-in Syndrome||Device: Summit System||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Device Feasibility|
|Official Title:||Brain-Computer Interface Implant for Severe Communication Disability|
|Estimated Study Start Date :||October 2022|
|Estimated Primary Completion Date :||October 2023|
|Estimated Study Completion Date :||October 2023|
Experimental: Summit system
Implantation of Summit system, consisting of one or two Medtronic Activa(R) RC+S grids with wireless communication capabilities.
Device: Summit System
Surgical implantation of the Summit system (consisting of one or two Medtronic Activa(R) RC+S grids with wireless communication capabilities) for Safety and efficacy testing of the Medtronic Summit System.
- Safety of Summit System as assessed by the number of adverse events [ Time Frame: Up to 52 weeks ]Record all adverse events on adverse events case report forms.
- Safety of Summit System as assessed by change in neurological deficits [ Time Frame: Immediately before device implantation, immediately after device implantation and 4-5 weeks after device implantation ]Pre- and post-surgical neurological/neurosurgical examinations to assess neurological deficits.
- Safety of Summit System as assessed by the status of stimulation [ Time Frame: Up to 52 weeks ]Verify that stimulation remains switched off (status is on or off).
- Efficacy of Summit System as assessed by change in letters spelled per minute [ Time Frame: Weekly up to 52 weeks ]Letters spelled per minute while copying a 30 character sentence during weekly assessments.
- Efficacy of Summit System as assessed by ability of participant to trigger the caregiver calling signal [ Time Frame: Up to 52 weeks ]Ability to trigger the caregiver calling signal (yes or no) will be used in assessing the efficacy of the Summit System.
- Change in Quality of Life as assessed by the ACSA [ Time Frame: Every 12 weeks up to 52 weeks ]Change in responses to Anamnestic Comparative Self-Assessment (ACSA) every 12 weeks. This biographical +5 and -5 scale compares current quality of life to the participant's memories of the best period in their life and their worst period ever.
- Frequency of use of Summit System per day [ Time Frame: Up to 52 weeks ]Patterns of home use of the Summit system captured by logs of participants' use of the device
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||22 Years to 75 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Age between 22-75 years.
Clinical diagnosis of chronic Locked-In Syndrome (LIS) certified by an independent board-certified neurologist, defined here as impairments of voluntary motor control that are widespread and severe enough to prevent independent initiation and maintenance of communication, spoken or otherwise, without the assistance of a caregiver. Diagnosis of LIS requires exclusion of cognitive impairments as a cause for impaired communication (see Exclusion Criteria). For inclusion in this study, participants may have one of the following clinical variants of LIS:
a. "Classic" Locked-In Syndrome, with the following signs documented on neurological examination i. Quadriplegia ii. Bulbar palsy iii. Anarthria iv. Partial or complete preservation of vertical eye movements and upper eyelid movements, or b. "Incomplete" Locked-In Syndrome, with the aforementioned signs of "Classic" LIS, documented on neurological examination, except that voluntary movements other than upper eyelid and vertical eye movement may be preserved, albeit still severe enough to prevent independent initiation and maintenance of communication, without the assistance of a caregiver. Preserved voluntary movements may include: i. Horizontal eye movements ii. Facial movements iii. Movements of the extremities not sufficient to reliably operate a joystick or mouse
Clinical diagnosis of, and confirmatory/exclusionary testing consistent with, one of the following irreversible or progressive neurological disorders as the cause for chronic Locked-In Syndrome, as defined above:
a. Permanent lesion of corticospinal and corticobulbar tracts in the ventral pons (basis pontis) due to ischemic stroke, hemorrhage, or trauma, based on the following: i. Documented history of acute ischemic or hemorrhagic brainstem stroke or traumatic brainstem injury at onset of LIS ii. Ancillary testing including the following:
1. Brain MRI confirming a chronic lesion of the ventral pons, with no change on serial images at least 1 month apart, consistent with findings on neurological examination, involving at least 50% of the cross-sectional area on both sides of the basis pontis on at least one axial section 2. Absence of lesions on brain MRI that could contribute to communication impairment, including lesions of Broca's or Wernicke's areas, or sensorimotor cortex 3. EEG demonstrating posterior basic rhythm reactive to eye opening and closing iii. No clinical evidence of improving communication ability for at least 1 year prior to recruitment, confirming chronic LIS b. Diagnosis of Amyotrophic Lateral Sclerosis (ALS), certified by an independent board-certified neurologist with expertise in neuromuscular disorders, satisfying the following El Escorial World Federation of Neurology diagnostic criteria for probable, laboratory supported, or definite ALS: i. Signs of lower motor neuron (LMN) degeneration by neurological examination (weakness, atrophy, and fasciculations), electrophysiological (electromyographic findings of denervation), or neuropathological determination (muscle biopsy) in bulbar and at least two of three spinal regions (cervical, thoracic, lumbosacral), or in all three spinal regions ii. Signs of upper motor neuron (UMN) degeneration by clinical examination (spasticity, hyperreflexia, pseudobulbar affect, pathological reflexes) in bulbar and at least two of three spinal regions (cervical, thoracic, lumbosacral), or in all three spinal regions iii. Progressive spread of signs within a region or to other regions, together with the absence of electrophysiological or neuroimaging evidence of other disease processes that might explain clinical and electrophysiological signs of LMN and/or UMN degeneration (see below) iv. Confirmatory testing including:
- Electromyographic findings of denervation (reduced recruitment, large motor unit action potentials, and fibrillation potentials) in clinically involved regions, including 3 of the following 4 muscle regions: bulbar, cervical, thoracic, and lumbosacral
- Nerve conduction studies confirming absence of demyelination as an explanation for aforementioned LMN signs
- Neuroimaging, including brain and spine MRI, ruling out brain or spinal lesions (spinal cord or root compression) that could explain aforementioned LMN or UMN signs
- Clinical laboratory examinations, determined by clinical judgment, to ascertain possible ALS-related syndromes v. History, physical, and laboratory examinations ruling out alternative diagnoses as cause of aforementioned clinical syndrome, including monoclonal gammopathy, autoimmune motor system degeneration, hyperthyroidism, hyperparathyroidism, paraneoplastic syndrome, infections of the central nervous system, toxic-metabolic disorders, or spinal cord injury due to trauma, electric shock, radiation therapy, vasculitis, ischemia, hemorrhage, or spondylotic myelopathy vi. No clinical evidence for improving communication ability for at least 6 months, confirming chronic LIS
- Reliable means of communicating with caregiver(s) before entering the study, for example using vertical eye movements or eye blinking. Assessment of communication capabilities may be made by a physiatrist, a speech therapist, and/or an occupational therapist.
- Residence within a reasonable driving distance from the JHU research team
- Medically stable, including stable respiratory function, with or without artificial ventilation (see Section 12.2.3, Section 12.2.6, and Section 12.2.11).
- Surgical clearance by the participant's primary healthcare provider, study physicians, and any necessary consultants
- Stable psychosocial support system with caregiver(s) capable of monitoring the participant throughout the study. Caregivers must be willing and able to be present and provide routine care during all study activities except during hospitalization for device implantation.
- Ability to understand and comply with study session instructions determined through the regular administration of simple study questionnaires.
- Strong and frequent muscle spasms not controlled by medication
- Recent or remote history of brain tumor or tumor resection in any location
- Cognitive impairments, according to neurological examination and neuropsychological testing, that contribute to impaired communication, or that could interfere with informed consent or participation in study activities
- "Complete" Locked-In Syndrome without any voluntary movement, including vertical eye movements or blinking, without any reliable means of communicating with caregivers or others.
- Known allergy to implanted materials
- Contraindications to MRI prior to implantation (inability to lie flat in the scanner, MRI-incompatible metal objects in or attached to the body, claustrophobia)
- Brain lesions that involve potential targets for implantation of BCI electrodes in sensorimotor cortical areas
- No clearly identifiable targets for implantation of BCI electrodes after two pre-implantation functional magnetic resonance imaging (fMRI) localizer scans. Targets are identified as cortical areas of activation during attempted movements and/or speech.
- Severe psychiatric illness that could interfere with informed consent or participation in study activities
- Persistent suicidal ideation within the past 12 months or prior suicide attempt
- Medical conditions contraindicating surgery or chronic device implantation
- Treatment with immunosuppressive drugs
- Chronic or acute medical condition that is anticipated to require surgery, radiotherapy, chemotherapy, immunosuppression, and/or MRI
- Pregnant (confirmation through blood test), planning to become pregnant (sexually active without using effective birth control), or nursing an infant.
- Visual impairment that would prevent use of computer monitor
- Active cancer within the past year
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04576650
|United States, Maryland|
|Johns Hopkins Hospital|
|Baltimore, Maryland, United States, 21287|
|Principal Investigator:||Nathan Crone, MD||Professor of Neurology, Johns Hopkins University|
|Responsible Party:||Johns Hopkins University|
|Other Study ID Numbers:||
U01DC016686 ( U.S. NIH Grant/Contract )
|First Posted:||October 6, 2020 Key Record Dates|
|Last Update Posted:||November 7, 2022|
|Last Verified:||November 2022|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||Yes|
Nervous System Diseases